Esmolol hydrochloride (Brevibloc) is a cardioselective (3, adrenergic receptor blocking agent. It has a rapid onset and short duration of action with an elimination half-life of only 9 min. A bolus of esmolol 1.5-3 mg kg" 1 has been shown to attenuate the increase in heart rate (HR) and mean arterial pressure (MAP) associated with tracheal intubation [1] . Whilst attenuation of this pressor response is desirable, excessive negative chronotropic and inotropic action of a PJ receptor blocker may reduce coronary perfusion and precipitate heart failure in susceptible patients [2] .
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This study was undertaken to observe the change in haemodynamic variables, including cardiac output (Q) and stroke volume (SV), in healthy anaesthetized patients, after a bolus dose of esmolol 100 or 200 mg. The patients were allocated randomly to one of three groups. The trial solution (group A, 0.9% saline 20 ml; group B, esmolol 100 mg in 20 ml; and group C, esmolol 200 mg in 20 ml) was then administered i.v. over 30 s. Readings were obtained 30 s after injection of the trial drug and then at 1-min intervals for 5 min. The anaesthetic then continued as appropriate. The results were calculated as percentage change in the readings before injection (to remove inter-patient variations in baseline readings). Data were analysed using the unpaired Student's t test. Significance was accepted at P < 0.05.
METHODS AND RESULTS

Hospital
There was no significant difference in height, weight, age, gender or baseline haemodynamic readings between the three groups. Mean age was 38.4 (range 18-60) yr, mean height 170.1 (SEM 1.60) cm and mean weight 71.1 (1.71) kg. Mean values before injection and percentage changes in haemodynamic variables are shown in table I.
There was a statistically significant decrease in HR (P < 0.05) in both esmolol groups compared with placebo every 1 min after injection. There was a significantly greater decrease in the 200-mg group until 4 min, compared with the 100-mg group (P < 0.05). The 100-mg group showed a statistically significant decrease in SV up to 2 min compared with placebo (P < 0.05). There was a statistically significant decrease in the esmolol 200 mg group compared with placebo and the esmolol 100 mg group until 4 min (P < 0.05). The decrease in Q in both esmolol groups was significant (P < 0.05) and was greatest at 1 and 2 min after injection. There was also a significant difference between the two esmolol groups until 4 min after injection (P < 0.05), with a maximal difference of 10 % at 1 min. Both esmolol groups showed a significant decrease in MAP (P < 0.05) with no significant difference between them.
COMMENT Esmolol hydrochloride is a new cardioselective ^t blocker. It is a phenoxypropanolamine that is metabolized rapidly by esterases in red blood cell. Its acid metabolite has only 1/1500 the p adrenoreceptor blocking activity of esmolol. The rapid onset of action and short elimination half-life of 9 min makes this drug useful in controlling acute increases in HR and MAP. Esmolol is licensed for use as an infusion following a loading dose of 500 ug kg" 1 min" 1 and studies have shown that bolus doses of up to 3 mg kg" 1 attenuate the increase in the rate-pressure product after tracheal intubation. Laryngoscopy and tracheal intubation are associated with an increase in sympathetic activity [3] . The increase in cardiac workload may precipitate myocardial ischaemia and acute heart failure in susceptible patients [4] .
SV and Q were measured using suprasternal Doppler ultrasonography, a technique that has been validated for the ODM 1 machine [5] . This study recorded the effect of bolus doses on haemodynamic variables and has shown that in unstimulated anaesthetized patients, i.v. administration of a bolus of esmolol produces a clinically significant reduction in Q compared with placebo. This is caused principally by a significant reduction in HR. Any negative inotropic action of the drug may be compensated by a longer diastolic time, thus allowing greater ventricular filling and so accounting for only a minimal reduction in SV. The decrease was of statistical significance but of no clinical importance as the largest reduction was approximately 4 ml at 1 min after a 200-mg bolus dose compared with placebo. In patients with reduced ventricular compliance caused by cardiac disease however, such a compensatory mechanism might fail, allowing SV to decrease with a greater reduction in Q. Compared with 200 mg, the 100-mg dose produced a lesser but still statistically significant decrease in Q. A reduction in Q may lead to a decrease in coronary artery perfusion compounding any reduction in perfusion pressure caused by a decrease in MAP. This may precipitate myocardial ischaemia in susceptible patients [6] and a smaller dose may be preferable.
